Assessing a personalized health platform project in the Gulf

The context

The project: a platform combining patients’ genomic data, medical records and lifestyle data to recommend personalized treatments. European funding was being considered. Before going further, the investor wanted an independent view.

What we analyzed

1. The regional landscape. Public initiatives in health AI, particularly in the UAE and Saudi Arabia, existing platforms and comparable cases.
2. The features. Genomic data integration, health record analysis, treatment recommendations, risk prediction.
3. The technical components. Data pipeline, choice of models for each use, interoperability with existing medical records.
4. Data and security. Storage, access control, anonymization, consent management.
5. The metrics. Accuracy of recommendations, response time, adoption by doctors, effects on patient health.
6. The regulatory framework. Data protection and health data rules in the UAE, Saudi Arabia, Qatar and Bahrain, cross-border transfer rules, medical device regulation, regulatory sandboxes.

Points to watch

• Where the data goes. Several countries strictly control health data leaving their territory. This constraint shapes the architecture from the start: hosting, choice of providers, multi-country operation.
• The status of the software. A tool that recommends treatment may fall under medical device regulation. Timeline and budget depend on it.
• Explainability. A doctor needs to understand why a recommendation is made before acting on it.
• Consent. Procedures must be adapted to each country, especially for genetic data.

In healthcare, the first question is not whether the model is good, but where the data is allowed to go.

What we take away

For an investor, a feasibility study is worth its list of conditions: what it will take for the project to hold up, and in what order. Regulatory and data questions are not implementation details: they decide what is possible.

Share on LinkedIn →